Parallax Volatility Advisers’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-24,443
| Closed | -$570K | – | 1589 |
|
|
2025
Q2 | $423K | Sell |
24,443
-3,907
| -14% | -$72.3K | ﹤0.01% | 1215 |
|
|
2025
Q1 | $620K | Buy |
+28,350
| New | +$783K | ﹤0.01% | 1150 |
|
|
2024
Q1 | – | Sell |
-39,392
| Closed | -$2.36M | – | 1806 |
|
|
2023
Q4 | $2.36M | Buy |
+39,392
| New | +$2M | ﹤0.01% | 1110 |
|
|
2023
Q2 | – | Sell |
-89
| Closed | -$7.68K | – | 2367 |
|
|
2023
Q1 | $5.87K | Sell |
89
-31,791
| -100% | -$1.83M | ﹤0.01% | 2456 |
|
|
2022
Q4 | $1.65M | Sell |
31,880
-45,273
| -59% | -$2.4M | ﹤0.01% | 1474 |
|
|
2022
Q3 | $5.27M | Buy |
77,153
+29,090
| +61% | +$1.72M | 0.01% | 998 |
|
|
2022
Q2 | $2.17M | Buy |
48,063
+48,053
| +480,530% | +$2.19M | ﹤0.01% | 1311 |
|
|
2022
Q1 | $1K | Sell |
10
-10,926
| -100% | -$482K | ﹤0.01% | 2770 |
|
|
2021
Q4 | $517K | Buy |
10,936
+10,892
| +24,755% | +$429K | ﹤0.01% | 2165 |
|
|
2021
Q3 | $1K | Sell |
44
-46,370
| -100% | -$2.61M | ﹤0.01% | 2913 |
|
|
2021
Q2 | $2.93M | Buy |
+46,414
| New | +$2.39M | ﹤0.01% | 1485 |
|
|
2020
Q3 | – | Sell |
-393
| Closed | -$13K | – | 3028 |
|
|
2020
Q2 | $13K | Sell |
393
-14,003
| -97% | -$450K | ﹤0.01% | 2602 |
|
|
2020
Q1 | $386K | Buy |
14,396
+12,152
| +542% | +$431K | ﹤0.01% | 1813 |
|
|
2019
Q4 | $69K | Buy |
+2,244
| New | +$62.1K | ﹤0.01% | 2191 |
|
|
2018
Q1 | – | Sell |
-1,680
| Closed | -$36K | – | 2224 |
|
|
2017
Q4 | $36K | Buy |
+1,680
| New | +$24.7K | ﹤0.01% | 3387 |
|
Other funds holding APLS
Parallax Volatility Advisers's APLS Position: Q3 2025 in Review
Parallax Volatility Advisers sold out of Apellis Pharmaceuticals (APLS) in Q3 2025, closing a stake of 24,443 shares — an estimated $570K sold.
Parallax Volatility Advisers first reported a position in APLS in Q4 2017 and held it in 15 quarters. The position peaked at $5.27M in Q3 2022. 273 funds tracked by Wall St. Rank hold APLS as of Q3 2025.
- Parallax Volatility Advisers reported no remaining Apellis Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
- Parallax Volatility Advisers sold 24,443 Apellis Pharmaceuticals shares in Q3 2025, an estimated $570K.
- Parallax Volatility Advisers first reported a position in Apellis Pharmaceuticals in Q4 2017 and held it in 15 quarters.
- Parallax Volatility Advisers's Apellis Pharmaceuticals position peaked at $5.27M in Q3 2022.
- 273 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q3 2025.
Based on Parallax Volatility Advisers's 13F filing for Q3 2025, filed 14 Nov 2025.